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Abstract
Background: Double Diabetes (DD), type 1 diabetes (T1DM) + insulin resistance (IR), is associated with increased
risk of micro/macro-vascular complications and mortality. Obesity can contribute to the development of DD. This
study explored the prevalence of overweight/obesity and their association with DD in adults with T1DM.
Methods: Cross-sectional study of consecutive adults with T1DM attending diabetes clinics in a secondary care
hospital (January-November 2019). Estimated glucose disposal rate (eGDR) was used as a marker of IR, and an
eGDR < 8 was used to identify individuals with DD.
Results: One hundred seven adults with T1DM were included; female/male: 51/56; age [median (inter-quartile
range): 30.0 (23–51) years]; BMI 25.4 (22.8–30.0) kg/m2. Overweight/obesity prevalence was 57/107 (53.3 %)
[overweight: 30/107 (28 %); obesity: 27/107 (25.2 %)]. Compared to those with normal BMI, individuals with T1DM
and overweight/obesity had longer diabetes duration; higher total daily insulin dose; and higher DD prevalence:
48/57 (84.2 %) vs. 14/50 (28 %) (p < 0.01); with similar HbA1c. BMI correlated with total daily insulin dose (rho = 0.55;
p < 0.01). Individuals with DD were older, had longer duration of diabetes, higher HbA1c, and more adverse lipid
profile and microalbuminuria compared to those without DD.
Conclusions: Overweight/obesity is very common in adults with T1DM, and is associated with double diabetes.
BMI is positively associated with total insulin dose. Double diabetes is associated with adverse cardiovascular risk
profile and is also common in lean individuals with T1DM. Further research is needed to examine the impact of
overweight/obesity in people with T1DM and whether weight loss in this population can improve diabetes-related
outcomes.
Keywords: Type 1 Diabetes Mellitus, Obesity, Overweight, Double diabetes, Insulin resistance
Background
Obesity is a chronic disease that is closely associated
with insulin resistance and significant morbidity [1, 2].
The prevalence of obesity globally has tripled between
1975 and 2016 [3]. In England, the 2017 Health Survey
(HSE) revealed that 64.3 % of adults are overweight
(35.6 %) or have obesity (28.7 %) [4].
Type 2 Diabetes mellitus (T2DM) is typically linked to
obesity with 90 % of people with T2DM having a body
mass index (BMI) in the overweight or obesity range [5].
In contrast, individuals with Type 1 diabetes mellitus
(T1DM) are generally lean at diagnosis [6]. However,
studies from North America suggest an increasing
prevalence of overweight and obesity in people with
T1DM [6, 7]. Of note, in the Pittsburgh Epidemiology of
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Diabetes Complications study, 42 % of adults with
T1DM were overweight and 22.7 % had obesity after 18
years of follow up [6–8]. Despite such studies, data on
the prevalence of overweight and obesity in individuals
with T1DM from other populations/cohorts remain lim-
ited. Interestingly a recent review suggested that obesity
may be a contributing factor to the increasing incidence
of T1DM [9].
Double diabetes (DD) is a term introduced to describe
individuals with T1DM who also have features of insulin
resistance [10]. Whilst there have been different defini-
tions for DD, estimated glucose disposal rate (eGDR)
has recently been proposed as a good marker of insulin
resistance that is easy to measure in clinical practice
[10]. As such, a cut-off eGDR value of < 8 in people with
T1DM has been proposed to identify individuals with
DD [10]. DD is associated with increased risk of micro-
and macrovascular complications, as well as higher car-
diovascular disease (CVD) and all-cause mortality [10,
11].
Given the paucity of relevant data, this study aimed to
examine the prevalence of overweight and obesity in
adult individuals with T1DM. A secondary study aim
was to examine the associations between overweight/
obesity and DD in this population.
Methods
We conducted a cross-sectional study examining con-
secutive adults with T1DM who attended the Young
Adult Diabetes Clinic (individuals with age between 18
and 25 years) and the General Adult Diabetes Clinic (in-
dividuals > 25 years old) between 1st January and 25th
November 2019 at Southmead Hospital, North Bristol
NHS Trust, Bristol, UK. All investigations were per-
formed as part of routine clinical care. The Patient
Safety, Assurance and Audit (PSAA) committee at North
Bristol NHS Trust (the ethics committee at the trust
which approves clinical audits) approved this audit
(audit number: CA8757). Consent was not needed as
this was a retrospective audit performed as part of a ser-
vice evaluation, rather than a research study – this was
approved by the PSAA committee. Only clinically avail-
able data, as part of routine care, was included in the
audit. The reporting of the study was carried out in ac-
cordance with STrengthening the Reporting of OBserva-
tional studies in Epidemiology (STROBE) guidelines on
observational studies.
The T1DM diagnosis was determined based on the
age of diagnosis, presence of T1DM-related autoanti-
bodies (GAD, IA-2, and zinc 8 transporter), the meas-
urement of urinary or blood c-peptide, and history of
diabetic ketoacidosis in accordance with the Association
of British Clinical Diabetologists (ABCD) criteria for
diagnosing T1DM [12]. Participants were included in
the study if they fulfilled any of the following criteria: (1)
low urine or blood c-peptide, regardless of age of diag-
nosis; (2) two or more positive T1DM-related autoanti-
bodies, regardless of age of diagnosis; (3) one positive
T1DM-related autoantibody, and diagnosed < 30 years of
age; (4) history of diabetic ketoacidosis (DKA), and diag-
nosed < 30 years of age; (5) diagnosed < 20 years of age,
regardless of T1DM-related autoantibody status. Partici-
pants with T2DM, maturity onset diabetes of the young
(MODY), diabetes secondary to underlying medical con-
ditions (e.g. due to pancreatitis or steroid induced dia-
betes), and individuals where the diabetes diagnosis was
not clear or yet confirmed were excluded from this
study.
Overweight was defined as a BMI of 25-29.9 kg/m2,
and obesity as a BMI ≥ 30 kg/m2. For people of Asian
ethnic background, BMI cut-offs of 23-27.4 kg/m2 and
≥ 27.5 kg/m2 were used to identify people with over-
weight and obesity, respectively [13].
Participants’ data including height, weight, blood pres-
sure, medications and past medical history, as well as
biochemistry information including lipid profile and
haemoglobin A1c (HbA1c – measured by high perform-
ance liquid chromatography) were collected from elec-
tronic Participants’ records. Hypertension was defined as
recorded blood pressure > 140/90mmHg; use of blood
pressure lowering medications; or a documented rele-
vant diagnosis in the electronic Participant record [14].
Estimated glucose disposal rate (eGDR) was calculated
as a validated proxy of insulin resistance based on the
following formula: eGDR = 19.02 – (0.22 x BMI [kg/m2)
– (3.26 x hypertension status [yes = 1, no = 0]) – (0.61 x
HbA1c [converted from IFCC mmol/mol to NGSP %])
[10]. An eGDR value of < 8 was used to identify individ-
uals with DD [10]. Data were collected, anonymised and
stored on a secure NHS computer in line with data pro-
tection guidelines.
Statistical analysis
Data are presented as median and interquartile range
(IQ) or numbers (percentages), unless stated otherwise.
Data were checked for normality using Histogram and
Shapiro-Wilk test. Between groups comparisons, normal
BMI vs. overweight/obesity, were assessed using the
Mann-Whitney U test, or chi-square for frequencies.
Correlations were assessed using Spearman rank-order
correlation coefficient, as appropriate. A p-value of <
0.05, 2-tailed, was considered statistically significant.
Data were analysed using PASW statistics 26 package
(SPSS Inc., Chicago, USA) [15].
Results
In total, 198 individuals with diabetes were reviewed in
the participating diabetes clinics during the study period.
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Of those, 107 were eligible for inclusion (Fig. 1). Table 1
summarizes demographics and pertinent clinical charac-
teristics for the entire study cohort and by weight sub-
group category (normal BMI, overweight, and obesity).
The study population was mainly of young adults with
balanced numbers of men and women and long diabetes
duration > 10 years. Ethnicity was documented in 72 par-
ticipants (72/107; 67.3 %); of those with documented
ethnicity, one Participant was of Asian ethnic back-
ground (1/72; 1.4 %), and the rest were White Caucasian
(71/72; 98.6 %). Participants with overweight/obesity
were older, had higher total daily insulin dose, and
higher prevalence of hypertension compared to normal
BMI. HbA1c and lipid profile were similar between Par-
ticipants with normal weight and those with overweight/
obesity.
The prevalence of overweight/obesity was 57/107
(53.3 %) [overweight: 30/107 (28 %); and obesity: 27/107
(25.2 %)]. A moderate association between increasing
BMI and total daily insulin dose (rho = 0.55, p < 0.01)
was noted (Table 2).
The prevalence of DD in the study cohort was 62/107
(57.9 %). There was a strong relationship between BMI
and DD prevalence (Table 1), and all study Participants
with T1DM and obesity had DD (27/27, 100 %). Individ-
uals with DD were older, had longer duration of dia-
betes, higher HbA1c despite higher total insulin doses,
more adverse lipid profile and more microalbuminuria
compared to those without DD. A comparison between
individuals with and without DD is summarised in
Table 3. The relative risk (RR) of having DD in the pres-
ence of hypertension, elevated Hba1c (> 8 %, 65mmol/
mol) or elevated BMI (> 25 kg/m2) was 2.07 (95 % CI:
1.67–2.57; p < 0.0001), 2.03 (95 % CI: 1.25–3.29; p =
0.0042) and 3.12 (95 % CI: 1.97–4.94; p < 0.0001),
respectively.
Surprisingly, a quarter of lean individuals with T1DM
had evidence of DD. A comparison between lean indi-
viduals with and without DD is summarised in Table 4.
Lean individuals with DD, compared to those without,
took similar total daily insulin dose, but were older, had
higher HbA1c, and more microalbuminuria (Table 4).
Discussion
This study highlights the high prevalence of overweight
and obesity in adults with T1DM. The prevalence of
overweight/obesity in our study sample (53.3 %, median
age of 30 years) is close to the prevalence of overweight/
obesity within the 25–34 year age group in the general
population in England (54.0 %) [4]. Furthermore, the
proportion of adults with T1DM who had obesity in our
cohort (25.7 %) is similar to that reported by Conway
et al. in North America (22.7 %) [7]. This suggests that
people with T1DM are at similar risk to obesity as the
general population. This requires more attention, and
highlights the need for more research to better under-
stand the clinical consequences of overweight/obesity in
T1DM and the impact of treatment strategies.
Fig. 1 Flow chart of eligible study participants summarising the reasons for inclusion or exclusion. BMI: body mass index; DKA: diabetic
ketoacidosis; yr: year; +ve: positive; ↓: low
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In addition, we found an association between the dur-
ation of T1DM and overweight/obesity. This is probably
caused by similar factors that contribute to weight gain
with increasing age, including reduced basal metabolic
rate, fat free mass, and physical activity with ageing; and
to hormonal changes that occur during the ageing
process [16]. Moreover, we also noted that people with
T1DM and overweight/obesity required higher doses of
insulin to achieve similar glycaemic control to those with
normal BMI. As insulin treatment may promote weight
gain in people with T2DM and T1DM [17, 18], this cre-
ates a vicious cycle in this population; where over-
weight/obesity will result in the need for more insulin to
overcome insulin resistance, whilst injecting more insu-
lin would promote weight gain. Subsequently, the rela-
tionship between insulin treatment and weight gain in
people in T1DM is probably bi-directional, and adds fur-
ther challenges to the management of diabetes in this
population. Indeed, diabulimia, an eating disorder where
a participant with T1DM does not inject insulin in order
Table 1 Selected key study relevant demographic and clinical characteristics of the entire study cohort of adults with type 1
diabetes (T1DM), and by weight sub-group based on body mass index (BMI). Data are presented as median and interquartile range
(IQ), and as percentages for frequencies. An estimated glucose disposal rate (eGDR) cut-off value of <8 was applied to identify
individuals with double diabetes (T1DM combined with insulin resistance). Microalbuminuria was defined as urine albumin/
creatinine ratio >3 mg/mmol. Hypertension was defined as blood pressure >140/90 mmHg or a documented relevant diagnosis in
the electronic Participant record. ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; BMI: body







Normal BMI(n=50) Overweight (n=30) Obesity(n=27) Overweight/obesity(n=57)
Age at clinic (years) 30.0 (23.0-49.5) 26.0 (22.0-47.3) 30.5 (23.0-54.0) 38.0 (25.0-51.0) 34 (23.5-51.0)
Age at diagnosis (years) 17.0 (11.0-27.0) 18.0 (11.0-27.5) 18.0 (11.8-28.3) 15.0 (7.0-25.0) 17.0 (9.0-27.5)
Diabetes duration (years) 12.0 (5.5-23.5) 9.5 (4.0-17.0) 12.0 (7.5-25.0) 19.0 (10.0-31.0) 15.0 (9.0-27.0)*
Female [n (%)] 51 (48) 22 (44) 15 (50) 14 (52) 29 (51)
Body weight (kg) 74.3 (63.6-87.4) 63.8 (60.1 -73.7) 74.5 (68.5-81.9) 93.9 (87.4-111) 82.0 (74.0-95.7)*
BMI (kg/m2) 25.4 (22.8-29.8) 22.8 (20.6-23.9) 26.3 (25.8-27.7) 34.4 (31.2-37.8) 29.4 (26.1-34.3)*
HbA1c (mmol/mol) 70.0 (62.0-80.0) 70.0 (61.0-81.5) 70.5 (61.8-79.0) 70.0 (63.0-81.0) 70.0 (63-79.5)
Total Insulin dose (units) 49.0 (36.0-65.0) 42 (30.9-53.8) 51.5 (34.8-65.5) 78.0 (60.0-120.0) 60 (46.0-83.0)*
Insulin dose (unit/kg/day) 0.68 (0.53-0.89) 0.66 (0.48-0.76) 0.67 (0.51-0.86) 0.85 (0.56-1.1) 0.75 (0.56-0.95)*
Total Cholesterol (mmol/L) 4.3 (3.6-4.9) 4.2 (3.5-4.9) 4.4 (3.6-4.9) 4.4 (3.8-5.0) 4.4 (3.6-5.0)
Triglyceride (mmol/L) 1.1 (0.7–1.7) 1.0 (0.7-1.4) 1.2 (0.7-1.8) 1.3 (0.9-2.0) 1.3 (0.8-1.8)
HDL Cholesterol (mmol/L) 1.4 (1.2-1.8) 1.6 (1.3-1.9) 1.5 (1.2-1.9) 1.3 (1.1-1.5) 1.4 (1.1-1.7)*
LDL Cholesterol (mmol/L) 2.3 (1.7-2.9) 2.2 (1.6-2.6) 2.3 (2.0-3.0) 2.8 (1.8-3.4) 2.5 (1.9-3.1)
Hypertension, [n (%)] 20 (19) 4 (8) 7 (23) 9 (33) 16 (28)*
Statins [n (%)] 33 (31) 11 (22) 8 (27) 14 (52) 22 (39)
ACEI/ARB [n (%)] 22 (21) 4 (8) 6 (20) 12 (44) 18 (32)*
Metformin [n (%)] 9 (8) 2 (4) 1 (3) 6 (22) 7 (12)
Microalbuminuria, [n (%)] 17 (16) 5 (10) 5 (17) 7 (26) 12 (21)
eGDR 7.4 (5.7-8.7) 8.7 (7.4-9.7) 7.4 (6.0-8.2) 4.5 (3.7-6.8) 6.3 (4.5-7.6)*
Double diabetes, [n (%)] 62 (58) 14 (28) 21 (70) 27 (100) 48/57 (84)*
Table 2 Correlation between study pertinent variables by Spearman rank-order correlation coefficient (rho). BMI, body mass index;
HbA1c, haemoglobin A1c. *P < 0.05 (2-tailed); **P < 0.01 (2-tailed)
BMI (kg/m2) Age at clinic (years) Diabetes duration (years) Total insulin dose (units) HbA1c (mmol/mol)
BMI (kg/m2) 0.22* 0.27** 0.55** 0.12
Age at clinic (years) 0.44** 0.02 0.02
Diabetes duration (years) 0.18 0.01
Total insulin dose (units) 0.20*
HbA1c (mmol/mol)
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to lose weight, is a serious problem in those affected
with significant risk of DKA and mortality [19]. There-
fore, further research is needed to better understand the
pathophysiology and consequences of overweight/obesity
in people with T1DM [10, 20].
Overall, three quarters of adults with T1DM who were
at least overweight in our study had DD. This finding
was even stronger in the study participants with obesity,
with all these individuals having DD. Interestingly, a
quarter of lean adults with T1DM also had DD. This
could be due to age, lean individuals with DD where
older than lean individuals without DD, while total daily
insulin dose doesn’t seem to be a factor. It could also be
related to other unmeasured factors, for example, waist
circumference, ethnicity, family history of insulin resist-
ance, and physical activity. Notably, large observational
studies suggest that individuals with DD have a higher
risk of micro-/macro-vascular complications and mortal-
ity compared to people with T1DM without insulin re-
sistance [10]. Our study also showed that DD was
associated with microalbuminuria, hypertension and ad-
verse lipid profile suggesting increased CVD risk. Subse-
quently, overweight/obesity is an extra burden on the
health of people with T1DM, and, thus, interventions
aiming to prevent weight gain and/or that promote
weight loss might be beneficial in reducing the risk of
diabetes complications in this population. However,
there is a lack of data on interventions that are effective
in promoting weight loss/weight maintenance in people
with T1DM. Interventions such as very-low carbohy-
drate diet, glucagon-like peptide-1 (GLP-1) analogues,
sodium–glucose cotransporter 2 (SGLT2) inhibitors, and
bariatric surgery have been suggested by some research
groups [21–26]. SGLT2 inhibitors and GLP-1 analogues
are widely used in people with T2DM with favourable
impact on weight [23]. In the DEPICT-1 study, the use
of a SGLT2 inhibitor (Dapagliflozin 5.0 mg once a day)
was accompanied by a 2.96 kg weight loss at 24 weeks
compared to placebo in people with T1DM [25]. Simi-
larly, in the Lira-1 trail the use of a GLP-1 analogue (Lir-
aglutide 1.8 mg once a day) was associated with 6.8 kg
weight loss compared to placebo in individuals with
T1DM who were overweight [26]. However, the experi-
ence in using GLP-1 analogues in people with T1DM re-
mains limited [23, 24]; while the use and licensing of
SGLT2 inhibitors in individuals with T1DM have been
restricted due to the increased risk of diabetic ketoacido-
sis [23, 24]. In this respect, our study highlights the need
for more research to identify effective weight manage-
ment interventions, including establishing if the above
anti-hyperglycaemic agents could be safe and effective
for people with T1DM and overweight/obesity. Indeed,
such weight loss interventions/treatments may also con-
tribute to reduce the chronic inflammation present in
T1DM [27], which may be further exacerbated by
obesity.
Study Limitations
The findings should be considered within the context of
the study limitations, including the cross sectional na-
ture of the study that does not allow to ascertain caus-
ation, and the lack of power calculation. Due to the
retrospective nature of the study, we did not have infor-
mation on socio-economic, waist circumference, family
history of insulin resistance, or physical activity. In
addition, all patients were from a single centre, and
people with type 1 diabetes on insulin pump therapy
were not included. Subsequently, the generalisability of
the study findings may have been affected by these limi-
tations; however, the prevalence of obesity in our cohort
Table 3 A comparison between individuals with and without
double diabetes. An estimated glucose disposal rate (eGDR) cut-
off value of < 8 was applied to identify individuals with Double
Diabetes (T1DM combined with insulin resistance). Data are
presented as median and interquartile range (IQ), and as
percentages for frequencies. Microalbuminuria was defined as
urine albumin/creatinine ratio > 3 mg/mmol. Hypertension was
defined as blood pressure > 140/90 mmHg; taking medications
for hypertension; or a documented relevant diagnosis in the
electronic Participant record. ACEI, angiotensin-converting-
enzyme inhibitors; ARB, Angiotensin II receptor blockers; BMI:
body mass index; eGDR: estimated glucose disposal rate; HbA1c:




No (n = 45) Yes (n = 62)
Age at clinic (years) 24.0 (21.5–38.5) 37.0 (24.0-51.3)*
Age at diagnosis (years) 18.0 (11.0-25.5) 16.5 (9.0–29.0)
Diabetes duration (years) 9.0 (2.0–17.0) 14.0 (8.8–26.5)*
Female [n (%)] 22 (49) 29 (47)
Body weight (kg) 64.0 (61.1–74.3) 80.5 (73.1–94.2)*
BMI (kg/m2) 22.9 (20.7–24.3) 29.1 (25.3–34.1)*
HbA1c (mmol/mol) 63.0 (53.5–73.0) 72.5 (66.8–87.0)*
Total Insulin dose (units) 42.0 (30.8–54.5) 57.0 (42.3–80.5)*
Insulin dose (unit/kg/day) 0.65 (0.45–0.82) 0.71 (0.56–0.93)*
Total Cholesterol (mmol/L) 4.1 (3.5–4.9) 4.4 (3.6-5.0)
Triglyceride (mmol/L) 0.9 (0.6–1.3) 1.3 (0.9–1.8)*
HDL Cholesterol (mmol/L) 1.6 (1.3–1.9) 1.4 (1.1–1.7)*
LDL Cholesterol (mmol/L) 2.0 (1.6–2.5) 2.5 (1.8–3.2)
Hypertension, [n (%)] 0 (0) 20 (32)*
Statins [n (%)] 10 (22) 23 (37)
ACEI/ARB [n (%)] 3 (7) 19 (31)*
Metformin [n (%)] 5 (11) 9 (15)
Microalbuminuria, [n (%)] 2 (4.4) 15 (24)*
eGDR 8.9 (8.5–10.0) 6.1 (4.5–7.3)*
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of people with T1DM was similar to other observational
studies from North America [7].
Conclusions
Overweight/obesity is very common in adults with
T1DM, and is associated with double diabetes. BMI is
positively associated with total daily insulin dose in this
population. Double diabetes is associated with adverse
cardiovascular risk profile and is also common in lean
individuals with T1DM. Further research is needed to
examine the impact of overweight/obesity in people with
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BMI (kg/m2) 22.6 (20.1–23.5) 23.2 (22.0-24.6)
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Triglyceride (mmol/L) 0.9 (0.7–1.3) 1.3 (0.8–1.6)
HDL Cholesterol (mmol/L) 1.6 (1.3–1.9) 1.6 (1.4-2.0)
LDL Cholesterol (mmol/L) 2.0 (1.6–2.5) 2.2 (1.9-3.0)
Hypertension, [n (%)] 0 (0) 4 (29)*
Statins [n (%)] 7 (19) 4 (29)
ACEI/ARB [n (%)] 2 (6) 2 (14)
Metformin [n (%)] 4 (11) 3 (21)
Microalbuminuria, [n (%)] 0 (0) 5 (36)*
eGDR 9.0 (8.6–10.0) 7.1 (5.6–7.4)*
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